Fundraising FoxNextech Invest — 2024 Investments
7 investments dated 2024 · listed companies and verified rows first · show all
Autolus Therapeutics develops engineered T cell therapies targeting cancer and autoimmune diseases using proprietary cell programming technology; the company commercializes AUCATZYL, an FDA-approved CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia in adults, and maintains a clinical pipeline evaluating additional indications including pediatric leukemia, lupus nephritis, and multiple sclerosis.
London
Martin Pulé(Senior Vice President, Founder, Chief Scientific Officer)Christopher Williams(Senior Vice President, Chief Business Development Officer)Edgar Braendle(Executive Officer)inChristopher Vann(Executive Officer)inDavid Brochu(Executive Officer)inChristian Itin(Chief Executive Officer and Director)in
Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors.
BiotechHealthtechPhiladelphia, US
Martin Lehr(Founder)inJennifer Minai-Azary(Executive Officer)inAlex Levit(Executive Officer)Linda Beth West(Director)Richard Jay Berman(Director)Philip Kantoff(Director)in
Co-investorsOUP (Osage University Partners)Torrey Pines Investment
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPDeerfield Management CompanyForesite CapitalFrazier Life SciencesGeneral Catalyst+9 more
.png)
Relay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques.
AI & Machine LearningBiotechDeep TechCambridge, US
Donald A. Bergstrom(Executive Officer)inSanjiv K. Patel(Director, President and Chief Executive Officer)inSekar Kathiresan(Director)Douglas S. Ingram(Director)Mark Murcko(Director)Laura Shawver(Director)
Co-investorsCommonweal VenturesEcoR1 CapitalForesite CapitalNat TurnerSoftBank Vision FundCurie.Bio+2 more
Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.
BiotechHealthtechCarlsbad, US
Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)inAlan Fuhrman(Executive Officer)inTodd Harris(President, Chief Executive Officer and Director)inBhavesh Ashar(Chief Operating Officer)in
Co-investorsAlta PartnersBioBritCanaan PartnersRA Capital
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture Partners+9 more
Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.
BiotechHealthtechCambridge, US
Kevin Marks(Founder)in
Co-investorsGV (Google Ventures)Taiho Ventures, LLCAlexandria
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.